ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Choueiri Highlights the Latest in Genitourinary Cancer Research

Toni Choueiri, MD
Published: Wednesday, Apr 11, 2018



Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the latest treatments in genitourinary (GU) cancers.

At the 2018 State of Science SummitTM on Genitourinary Cancers, Dr Bradley McGregor discussed the landscape of advanced renal cell carcinoma (RCC) and the use of targeted therapy and immunotherapy in treatment. Immunotherapy research includes combinations such as nivolumab (Opdivo) and ipilimumab (Yervoy) and other VEGF inhibitors. Many phase III trials are comparing the efficacy of these agents with sunitinib (Sutent). Many of these trials have completed enrollment or are ongoing, so there is much to come in advanced RCC, says Choueiri.

Dr Guru Sonpavde spoke about integrating immunotherapy into chemotherapy regimens in advanced bladder cancer in the early-stage setting. Additionally, Dr Xiao Wei spoke about the importance of systemic therapy management across GU cancers. The focus was on PD-1/PD-L1 inhibitors and immunotherapy in general in the management of adverse events.
 


Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the latest treatments in genitourinary (GU) cancers.

At the 2018 State of Science SummitTM on Genitourinary Cancers, Dr Bradley McGregor discussed the landscape of advanced renal cell carcinoma (RCC) and the use of targeted therapy and immunotherapy in treatment. Immunotherapy research includes combinations such as nivolumab (Opdivo) and ipilimumab (Yervoy) and other VEGF inhibitors. Many phase III trials are comparing the efficacy of these agents with sunitinib (Sutent). Many of these trials have completed enrollment or are ongoing, so there is much to come in advanced RCC, says Choueiri.

Dr Guru Sonpavde spoke about integrating immunotherapy into chemotherapy regimens in advanced bladder cancer in the early-stage setting. Additionally, Dr Xiao Wei spoke about the importance of systemic therapy management across GU cancers. The focus was on PD-1/PD-L1 inhibitors and immunotherapy in general in the management of adverse events.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x